Drug Trial Radar · NCT04579666
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
Last checked: Nov 19, 2026Latest source record: Apr 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
249
Actual
Start
Sep 30, 2020
Primary completion
Mar 31, 2023
Study completion Jul 13, 2023
Sponsor
- Lead sponsor
- Apellis Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 8, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 24-month, Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pegcetacoplan in subjects with amyotrophic lateral sclerosis (ALS)
Conditions
- Amyotrophic Lateral Sclerosis
- Motor Neuron Disease
Interventions
Pegcetacoplan (APL-2)Drug
Complement (C3) Inhibitor
PlaceboOther
Sterile solution of equal volume to active arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- RTP: Combined Assessment of Function and Survival (CAFS) Rank Score (Joint-Rank Score) at Week 52Time frame: Week 52
- RTP: Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)Time frame: From first dose of study drug (Day 1) up to 56 days post last dose of study drug, approximately 60 weeks
- OLP: Number of Participants With Treatment-emergent Adverse Events and Treatment-emergent Serious Adverse EventsTime frame: From first dose of study drug (Week 52) up to 56 days post last dose of study drug, approximately 60 weeks
- RTP: Number of Subjects With Positive Response to Columbia-Suicide Severity Rating Scale (C-SSRS) up to Week 52Time frame: Baseline (Day 1) up to Week 52
- OLP: Number of Subjects With Positive Response to Columbia-Suicide Severity Rating Scale up to Week 104Time frame: From Baseline (Week 52) up to Week 104
Locations
60 sites in 14 countries. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California
University of Colorado
Aurora, Colorado
University of South Florida
Tampa, Florida
Augusta University
Augusta, Georgia
Indiana University
Indianapolis, Indiana
Johns Hopkins
Baltimore, Maryland
The Berman Center
Minneapolis, Minnesota
Hospital for Special Surgery
New York, New York
Austin Neuromuscular Center
Austin, Texas
University of Vermont Medical Center
Burlington, Vermont
Brain and Mind Centre
Camperdown, New South Wales, Australia
Central Coast Neurosciences Research
Erina, New South Wales, Australia
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia
Gold Coast University Hospital
Southport, Queensland, Australia
Nueor-Immunology Clinical Researh Education and Support Service (N-CRESS), Austin Health
Heidelberg, Victoria, Australia
AZ Sint-Lucas & Volkskliniek
Ghent, Belgium
Universitaire Ziekenhuizen Leuven (UZ Leuven)
Leuven, Belgium
Vseobecna fakultni nemocnice v Praze
Prague, Czechia
FORBELI s.r.o.
Prague, Czechia
Hopital Pellegrin
Bordeaux, France
Hôpital Neurologique Pierre Wertheimer
Bron, France
CHU Gabriel Montpied
Clermont-Ferrand, France
Hôpital Roger Salengro
Lille, France
CHU de Limoges Dupuytren 1
Limoges, France
CHU de Nice Hôpital Pasteur
Nice, France
Charité - Universitätsmedizin Berlin
Berlin, Germany
Medizinische Hochschule Hannover Klinik für Neurologie
Hanover, Germany
Universitätsklinikum Jena
Jena, Germany
Universitätsmedizin Rostock, Klinik und Poliklinik für Neurologie
Rostock, Germany
University of Ulm
Ulm, Germany
Beaumont Hospital
Dublin, Ireland
Ospedale Niguarda - Nemo Clinical Center - Fondazione Serena Onlus
Milan, Italy
Ospedale Civile S. Agostino Estense di Modena, Azienda Ospedaliero Universitaria di Modena
Modena, Italy
AOUP "P. Giaccone"
Palermo, Italy
Azienda Ospedaliera Universitaria di Torino - Città della Salute e della Scienza di Torino
Torino, Italy
National Hospital Organization Higashinagoya National Hospital
Aichi, Japan
National Hospital Organization Omuta National Hospital
Fukuoka, Japan
National Hospital Organization Asahikawa Medical Center
Hokkaido, Japan
National Hospital Organization Hyogo-Chuo National Hospital
Hyōgo, Japan
National Hospital Organization Iou National Hospital
Ishikawa, Japan
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.